The primary objective of Core B (Radiopharmacy) is to provide support to Project 1, Human Studies. Yttrium-90 radiolabeled chimeric T84.66 anti- CEA antibody will be used in Phase I and Phase II clinical trials for colon and breast cancer patients at the City of Hope National Medical Center. Indium-111 radiolabeled chimeric T84.66 antibody will be used for dosimetry purposes. iodine-1`23 rabiolabeled chimeric T84.66 fragments will be used for Phase I imaging studies. The radiopharmacy will support Project 1 by providing expertise and facilities to prepare radiolabeled antibodies and to provide quality control for these reagents. A protocol for large-scale preparation of In-111, Y-90 and I-123 labeled monoclonal antibodies is currently active. As part of its core activity the Radiopharmacy also supports the conjugation of the monoclonal antibody constructs to be used in the clinical trials. The secondary objective of Core B is to provide labeling for clinical development of novel constructs and chelates. In this way, the Core supports project 2 (Bioengineered Antibodies) and Project 3 (Antibody Chelates and Conjugates). The biochemical and radiological stabilities will be determined for these antibody preparations, providing this information for the filing of IND applications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope National Medical Center
United States
Zip Code
Sta Maria, Naomi S; Barnes, Samuel R; Weist, Michael R et al. (2015) Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells. PLoS One 10:e0142767
Kwok, Cheuk S; Frankel, Paul H; Lopatin, George et al. (2014) Using a single parameter to describe time-activity curves. Cancer Biother Radiopharm 29:83-6
Yazaki, Paul J; Lee, Brian; Channappa, Divya et al. (2013) A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 26:187-93
Ng, Thomas S C; Wert, David; Sohi, Hargun et al. (2013) Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res 19:2518-27
Specks, Ulrich; Ikle, David; Stone, John H (2013) Induction regimens for ANCA-Associated Vasculitis. N Engl J Med 369:1865-6
Fonge, Humphrey; Leyton, Jeffrey V (2013) Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice. Mol Imaging 12:191-202
Povoski, Stephen P; Davis, Paul D; Colcher, David et al. (2013) Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics. Expert Rev Mol Diagn 13:315-9
Barat, Bhaswati; Kenanova, Vania E; Olafsen, Tove et al. (2011) Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging. Mol Imaging Biol 13:526-535
Somlo, George; Spielberger, Ricardo; Frankel, Paul et al. (2011) Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res 17:174-82
Gagnon, Pete; Cheung, Chia-Wei; Lepin, Eric J et al. (2010) Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. Bioprocess Int 8:26-35

Showing the most recent 10 out of 112 publications